Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bac6.0
Bacopa Monnieri – Forschung
Überwiegend Mechanismus / Beobachtung
48 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Bacopa Monnieri sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2001–2026 mit einer typischen Studiengröße von 62 Teilnehmenden.
Basierend auf 48 Studien · 1 Meta-Analyse · 14 RCTs · 3,834 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
1geholfen· 47 weitere ohne bewertete Effektdaten
Nach Outcome
Cognitive functionVerbesserte Gedächtnisbildung und Erinnerungsvermögen · 8-12 weeks
Überwiegend Mechanismus / Beobachtung40 Studien
Neuroprotection & brain agingBDNF und antioxidativer Schutz des ZNS; schützt Neuronen während des Alterns · 8-12 weeks
Depression & moodModerate angstlösende und stimmungsstabilisierende Effekte · 8-12 weeks
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Sleep & insomnia
Überwiegend Mechanismus / Beobachtung3 Studien
Energy & fatigue
Überwiegend Mechanismus / Beobachtung3 Studien
Inflammation
Zu wenige bewertete Studien1 Studie
Glucose & metabolic
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 35 Studien mit messbaren Effekten gezogen
Untersuchte Personen
3,834
typische Studie: 62 Personen
Stärkste Designs
15
1 gepoolt, 14 randomisiert
Zeigte Nutzen
100%
1/1 Studien
Wie lange Studien liefen
1–4 Wochen
1
1–3 Monate
4
Untersuchte Populationen
General population4
Human subjects2
Healthy adults2
Schizophrenia patients1
Aktives Forschungsgebiet
34 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2014
200120132026
1Schizophrenia symptom managementSystematische ÜbersichtCited 2×n=103 · medium study2025
It is recommended that additional research elucidating the effects of Brahmi in other models of schizophrenia and the possible mechanisms of action be conducted.
Ayilara GO et al. · Nutritional neuroscience (2025)
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Data analysis was done by using themes.
The review found that Brahmi could reverse positive, negative, and cognitive symptoms of schizophrenia.
2Herbal medicine use patterns for epilepsy seizuresSystematische ÜbersichtCited 38×n=2,017 · very large study2019
Species with the highest use report were not those with pharmacological evaluation.
Auditeau E et al. · Journal of ethnopharmacology (2019)
Species with the highest use report were not those with pharmacological evaluation.
It will be pertinent to assess the pharmacological effects and safety of medicinal plants used mostly by traditional healers on predictive models of seizures.
5Prostate cancer managementSystematische ÜbersichtCited 3×2025
Despite strong evidence of efficacy of these plants to potentially improve the outcome of prostate cancer, clinical trials are required to evaluate which plants may be most efficacious and to determine effective dosing strategies, as well as the use of ayurvedic plants as standalone therapies or in combination with conventional prostate cancer treatments.
Jabbari P et al. · Integrative cancer therapies (2025)
As such, there is an urgent need for novel therapeutic options in treating this malignancy.
This review examines the pre-clinical evidence for Ayurveda medicinal plants such as Withania somnifera, Glycyrrhiza spp, Momordica spp, Boswellia, and Bacopa monnieri and their potential application in managing prostate cancer.
Several in-vitro and pre-clinical studies suggest potentials for these plants or their derivatives in preventing or treating prostate cancers.
6Type 2 diabetes mellitus and neurodegeneration managementSystematische ÜbersichtCited 1×2025
Network pharmacology and protein-protein interaction analyses confirm bacoside-A's regulatory roles in NOTCH signalling, insulin receptor expression, and hepatic enzyme modulation.
Dadhich A et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025)
Network pharmacology and protein-protein interaction analyses confirm bacoside-A's regulatory roles in NOTCH signalling, insulin receptor expression, and hepatic enzyme modulation.
Collectively, these findings validate BM as a viable, low-toxicity candidate for next-generation phytopharmaceutical development in the holistic management of diabetes and its complications.
7Cognitive function and nootropic effectsSystematische ÜbersichtCited 31×2023
Together, the results from the compiled studies highlight the nootropic effects and the inconsistencies regarding PDNs that require further research.Supplemental data for this article is available online at https://doi.org/10.1080/10408398.2021.2021137.
Lorca C et al. · Critical reviews in food science and nutrition (2023)
Bacopa monnieri improves language, learning and memory.
Withania somnifera (Ashwagandha) modulates anxiety and social-related cognitions.
Caffeine enhances attention and executive functions.
Srivastava P et al. · Current pharmaceutical design (2024)
Here, we focused on neurological problems as we examined the pharmacological and phytochemical characteristics of BME.
For their effective usage in neuroprotection and cognition, many clinical concerns and the synergistic potential of Bacopa extract have been investigated.
Alzheimer's disease is a neurological condition caused by the production of reactive oxygen species, which also causes amyloid-beta (Aβ) and tau protein aggregation and increases neuro-inflammation and neurotoxicity.
Vinod A et al. · Current topics in medicinal chemistry (2022)
The active constituents and metabolites responsible for the effects of BM could be bacoside A and B, bacopaside I and II, bacopasaponin C, betulinic acid, asiatic acid, loliolide, ebelin lactone, and quercetin.
We have also discussed CDRI-08, clinical trials, safety, emerging formulation technologies, as well as BM combinations, and dietary supplements.
The present review is a comprehensive and up-to-date analysis supported by the evidentiary proofs from pre-clinical studies, meta-analyses, and review papers related to natural phytochemicals' impact on neurodegenerative disorders like AD.
Khandia R et al. · Current Alzheimer research (2022)
The present review is a comprehensive and up-to-date analysis supported by the evidentiary proofs from pre-clinical studies, meta-analyses, and review papers related to natural phytochemicals' impact on neurodegenerative disorders like AD.
Luthra R et al. · Current pharmaceutical biotechnology (2022)
Variation in transcription and transduction pathways plays a vital role in the preventive measures of plants in such diseases.
Neurodegenerative diseases are generally caused by the depletion of proteins, oxidative and inflammatory stress, environmental changes and so on, with aging being the most important cause.
Natural compounds can be used in order to treat neurodegenerative diseases Medicinal plants such as Ginseng, Withania somnifera, Bacopa monnieri, Ginkgo biloba, etc. are some of the medicinal plants for the prevention of neurological symptoms.
Potential solutions to address research gaps are offered, for future research next steps, which is needed to strengthen the evidence and inform decisions.
Crawford C et al. · Journal of alternative and complementary medicine (New York, N.Y.) (2021)
Ingredients evaluated included Bacopa monnieri, choline, creatine, omega-3 fatty acids, Ginkgo biloba, ginseng, Rhodiola rosea, tyrosine, and valerian root, all in supplement form and compared with a placebo, at various serving sizes and durations of use.
Whereas certain trends regarding promising serving sizes or duration for use, are pointed to in this synthesis, when combined, studies are inconsistent and imprecise, and many are methodologically flawed.
Potential solutions to address research gaps are offered, for future research next steps, which is needed to strengthen the evidence and inform decisions.
The review demonstrates the neuroprotective potential of the Ayurveda herb Brahmi in several disorders including Alzheimer's disease, epilepsy, Parkinson's disease, Huntington's disease, cerebral ischemia and infarct and neoplasms.
Shalini VT et al. · Molecular biology reports (2021)
Numerous research have been undertaken across the globe to evaluate the neuroprotective potential of this herb.
This review collates and summarises current (as on May 2020) published literature on Brahmi as a neuroprotective in neurological and psychiatric disorders.
English language articles from databases PubMed, Scopus and Google scholar were searched using appropriate free keywords and MeSH terms related to the topic.
This comprehensive review covers literature up to the year 2020 highlighting all the anticancer efficacy along with signaling pathways activated by secondary metabolites found in bacopa plant.
Ghosh S et al. · Nutrition and cancer (2021)
In recent years, research on the biological effects of Bacopa monnieri has flourished as promising neuroprotective, memory boosting and more importantly as both chemopreventive and anti-neoplastic agent.
Each naturally synthesized chemical constituent identified from Bacopa monnieri leaf extract with different solvents, has significant anti-metastatic, anti-angiogenic and anti-proliferative activity on different type of cancer cells.
In this context, a substantial literature survey allows a deep understanding of the involvement of specific bioactive molecules along with the whole plant extract of Bacopa monnieri with their divergent effective molecular pathways.
Overall, nearly one-quarter (23%) of adults currently take a supplement to maintain or improve brain health or delay and reverse dementia.
However, other botanicals that affect stress, focus, attention, and sleep have also been procured by dietary supplement companies developing products for improving both, short and long-term brain health.
Botanicals are discussed in terms of available clinical efficacy data and current safety profiles.
18Systematische ÜbersichtCited 7×n=14 · very small study2023
Overall, this review found that there is a low quality of evidence regarding the efficacy of cognitive function and safety of herbal and nutritional medicines for older adults with and without SCI, due to a high risk of bias across studies.
Cave AE et al. · Systematic reviews (2023)
Overall, this review found that there is a low quality of evidence regarding the efficacy of cognitive function and safety of herbal and nutritional medicines for older adults with and without SCI, due to a high risk of bias across studies.
Additionally, further work needs to be done in classifying and understanding SCI and selecting appropriate trial primary outcomes before future studies can more accurately determine the efficacy of interventions for this population.
19BDNF modulation by botanicalsSystematische ÜbersichtCited 36×2017
Further clinical studies are mandatory to confirm botanicals as preventive agents or as useful adjuvant to the pharmacological treatment.
Sangiovanni E et al. · Neural plasticity (2017)
The effect of the active principles responsible for the efficacy of the extracts is reviewed and discussed as well.
The high number of articles published (more than one hundred manuscripts for 14 botanicals) supports the growing interest in the use of natural products as BDNF modulators.
The studies reported strengthen the hypothesis that botanicals may be considered useful modulators of BDNF in CNS diseases, without high side effects.